Syndax Pharmaceuticals Q3 2026 Earnings Report

Syndax Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.48
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Syndax Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $82.41 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Syndax Pharmaceuticals Announcement Details

• Quarter: Q3 2026
• Date: 11/2/2026
• Time: After Market Closes
• Conference Call Date: Monday, November 2, 2026
• Conference Call Time: 4:30PM ET

Syndax Pharmaceuticals (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older. The company is also associated with axatilimab, an antibody targeting the colony-stimulating factor 1 receptor (CSF-1R) pathway. Axatilimab, marketed as Niktimvo through a collaboration with Incyte, is approved in the United States for certain adults with chronic graft-versus-host disease after failure of at least two prior systemic therapies.

Founded in 2005 and headquartered in Waltham, Massachusetts, Syndax has historically advanced a pipeline of oncology and immunology candidates through internal research and strategic collaborations. The company is led by Michael A. Metzger, who serves as president and chief executive officer. Its products and development activities are primarily focused on the U.S. market, while its partnerships and clinical programs support broader international development and commercialization efforts.